TMEM43 and breast cancer: We benchmarked iMOKA on a dataset of 1038 mRNA-Seq breast cancer samples from the Cancer Genome Atlas (TCGA) Pan-Gyn cohort [21] (patients per class: basal 190, Her2 82, LumA 559, LumB 207) and tested how well the outputs of each approach could accurately predict the four classes.